<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CEFPODOXIME</span><br/>(cef-po-dox'eem)<br/><span class="topboxtradename">Vantin<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic</span>; <span class="classification">third-generation cephalosporin</span><br/><b>Prototype: </b>Cefotaxime sodium<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 mg, 200 mg tablets; 50 mg/5 mL, 100 mg/5 mL suspension</p>
<h1><a name="action">Actions</a></h1>
<p>Semisynthetic cephalosporin antibiotic with antibacterial activity resembling that of other third-generation cephalosporins.
         Stable in the presence of beta-lactamases. Highly active against gram-negative bacteria.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>It is effective against most common pathogens causing upper and lower respiratory infections. Effectively treats gonorrhea,
         otitis media, upper and lower respiratory infections, and skin and urinary tract infections, reducing or eliminating infection.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Gonorrhea, otitis media, lower and upper respiratory tract infections, urinary tract infections.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Skin and soft tissue infections.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to cephalosporins and other beta-lactam antibiotics; pregnancy (category B).</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal impairment, history of type I hypersensitivity reactions to penicillins; history of colitis or other GI disease; lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Respiratory Tract, Skin, and Soft Tissue Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 200 mg q12h for 10 d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 10 mg/kg/d divided q12h<br/><br/><span class="indicationtitle">Urinary Tract Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 100 mg q12h<br/><br/><span class="indicationtitle">Gonorrhea</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 200 mg as single dose<br/><br/><span class="indicationtitle">Otitis Media</span><br/><span class="rdage">Child <i>5 mo12 y</i>
                  				:</span> <span class="rdroute">PO</span> 10 mg/kg/d divided q1224h<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food to enhance absorption.</li>
<li>Give 1 h before or 2 h after an antacid.</li>
<li>Consult physician regarding patients with renal impairment (i.e., creatinine clearance less than 30 mL/min); dosage intervals
            should be every 12 h.
         </li>
<li>Patients on hemodialysis should be given usual dose 3 times weekly after hemodialysis.</li>
<li>Preparation of suspension: To either the 50 mg/5 mL strength or the 100 mg/5 mL strength, add 25 mL of distilled water, then
            shake vigorously for 15 seconds. Next, to the 50 mg/5 mL strength add 33 mL, or to the 100 mg/5 mL strength add 32 mL, of
            distilled water, and shake for at least 3 minutes.
         </li>
<li>Store suspension for up to 14 d in a refrigerator (2°8° C/36°46° F). Shake well before using.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Eye itching, cough, epistaxis, fever, decreased appetite, malaise. <span class="typehead">GI:</span> Diarrhea, nausea, vomiting, abdominal pain, soft stools, flatulance, <span class="speceff-life">pseudomembranous colitis</span> (rare). <span class="typehead">CNS:</span> rare: Headache, asthenia, dizziness, fatigue, anxiety, insomnia, flushing, nightmares, weakness. <span class="typehead">Urogenital:</span> Vaginal candidiasis. <span class="typehead">Skin:</span> Urticaria, rash, scaling, peeling. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">antacids</span>, <b>ranitidine</b> may decrease absorption. <span class="typehead">Food:</span> Food may increase the absorption. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 4050% absorbed from GI tract increased with food. <span class="typehead"> Onset:</span> Therapeutic effect in 3 d. <span class="typehead">Distribution:</span> Distributes well into inflammatory, pulmonary, and pleural fluid, and tonsils. Some distribution into prostate. 40% bound
      to plasma proteins. Distributed into breast milk. <span class="typehead">Elimination:</span> 80% excreted in urine. <span class="typehead">Half-Life:</span> 23 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Determine history of hypersensitivity reactions to cephalosporins and penicillins, and history of allergies, particularly
            to drugs, before therapy is initiated.
         </li>
<li>Lab tests: Perform culture and sensitivity tests before initiation of therapy and periodically during therapy, if indicated.
            Therapy may be instituted pending test results.
         </li>
<li>Report onset of loose stools or diarrhea. Although pseudomembranous enterocolitis (see Appendix F) rarely occurs, this potentially
            life-threatening complication should be ruled out as the cause of diarrhea during and after antibiotic therapy.
         </li>
<li>Monitor for manifestations of hypersensitivity (see Appendix F). Discontinue drug and report S&amp;S of hypersensitivity promptly.</li>
<li>Monitor I&amp;O rates and pattern: Especially important with high doses; report any significant changes.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report any signs or symptoms of hypersensitivity immediately.</li>
<li>Report loose stools, or diarrhea, especially if containing blood, mucus, or pus.</li>
<li>Complete the full course of drug therapy even if symptoms improve.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>